convalescent plasma treatment - versus standard of care - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 1.00 [0.94, 1.07]< 10%20 studies (20/-)51.9 %some concerncritical moderatecrucial-
deaths 0.98 [0.93, 1.05]< 10%29 studies (29/-)70.2 %some concerncritical moderatecrucial-
deaths (time to event analysis only) 0.95 [0.63, 1.45]< 136%4 studies (4/-)58.8 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.90 [0.64, 1.27]< 10%3 studies (3/-)72.2 %some concernnot evaluable moderateimportant-
clinical improvement 1.24 [0.85, 1.81]> 157%5 studies (5/-)86.3 %some concernserious moderateimportant-
clinical improvement (14-day) 2.27 [0.90, 5.72]> 10%1 study (1/-)95.9 %NAnot evaluable important-
clinical improvement (28-day) 1.61 [0.69, 3.76]> 174%3 studies (3/-)86.2 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 0.98 [0.27, 3.58]> 10%1 study (1/-)48.8 %NAnot evaluable important-
clinical improvement (time to event analysis only) 1.11 [0.77, 1.61]> 13%2 studies (2/-)71.5 %some concernnot evaluable moderateimportant-
death or ventilation 0.98 [0.94, 1.03]< 10%5 studies (5/-)79.2 %some concernnot evaluable moderateimportant-
hospital discharge 1.00 [0.94, 1.07]> 10%3 studies (3/-)52.3 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.75 [0.51, 1.09]< 144%5 studies (5/-)93.7 %some concernserious moderateimportant-
mechanical ventilation (time to event analysis only) 0.97 [0.62, 1.52]< 10%2 studies (2/-)55.5 %some concernnot evaluable moderateimportant-
viral clearance 1.10 [0.19, 6.30]> 10%2 studies (2/-)54.1 %some concernnot evaluable moderateimportant-
viral clearance by day 14 0.96 [0.77, 1.20]> 10%2 studies (2/-)35.7 %some concernnot evaluable moderateimportant-
viral clearance by day 7 0.87 [0.65, 1.16]> 10%2 studies (2/-)17.4 %some concernnot evaluable moderateimportant-
ICU admission 0.82 [0.35, 1.91]< 10%1 study (1/-)67.7 %NAnot evaluable non important-

safety endpoints 00

serious adverse events 1.25 [1.01, 1.56]< 132%4 studies (4/-)2.2 %some concernnot evaluable moderateimportant-
adverse events 1.08 [0.86, 1.37]< 10%2 studies (2/-)24.8 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.